<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552108</url>
  </required_header>
  <id_info>
    <org_study_id>UQuebecOutaouais</org_study_id>
    <nct_id>NCT02552108</nct_id>
  </id_info>
  <brief_title>A Single-Component CBT for GAD</brief_title>
  <official_title>Behavioural Experiments for Intolerance of Uncertainty: A Single-Component Treatment for Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universite du Quebec en Outaouais</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Concordia University, Montreal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universite du Quebec en Outaouais</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Generalized Anxiety Disorder (GAD) is a chronic condition that is characterized by excessive&#xD;
      and uncontrollable worry and anxiety. In Canada, 3 to 4% of the population suffer from GAD at&#xD;
      any point in time. These individuals have a lowered quality of life and are at risk for many&#xD;
      medical conditions such as coronary heart disease and cancer. Research suggests that both&#xD;
      pharmacological and psychological approaches are effective for treating GAD in the&#xD;
      short-term; however, psychological treatments appear to offer the greatest long-term&#xD;
      benefits. There exist a number of effective psychological treatments for GAD, most of which&#xD;
      fall into the category of cognitive-behavioural therapy or CBT. In the 1990s, a group of&#xD;
      Canadian investigators developed a CBT protocol for GAD that included four components. Data&#xD;
      from five clinical trials suggest that one of the four components is particularly important&#xD;
      for treatment success: experiencing uncertainty rather than avoiding it in everyday life.&#xD;
      Stated differently, learning to tolerate and deal with uncertainty appears to be the key to&#xD;
      decreasing worry and anxiety. Given this finding, the investigators have developed a new&#xD;
      treatment that exclusively targets intolerance of uncertainty: Behavioural Experiments for&#xD;
      Intolerance of Uncertainty or BE-IU. The goal of the current proposal is to test the efficacy&#xD;
      of BE-IU by comparing it to a Waiting List (WL) control condition. A total of 50 participants&#xD;
      with a primary diagnosis of GAD will be randomly assigned to either BE-IU or WL and will be&#xD;
      assessed at 5 time points ranging from pre-treatment to 12-month follow-up. The conditions&#xD;
      will be compared in terms of treatment efficacy and mechanisms. The investigators will also&#xD;
      examine the predictors of change during the 12-months following treatment. The proposed study&#xD;
      will produce data on the efficacy and mechanisms of a treatment for GAD that is less costly,&#xD;
      less complex and easier to disseminate than treatments that are currently available.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician's Severity Rating (CSR) of Anxiety Disorders Interview Schedule (ADIS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Structured diagnostic interview</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Penn State Worry Questionnaire (PSWQ)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Self-report questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worry and Anxiety Questionnaire (WAQ)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Self-report questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Anxiety Inventory (BAI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Self-report questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory-II (BDI-II)</measure>
    <time_frame>14 weeks</time_frame>
    <description>Self-report questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intolerance of Uncertainty Scale (IUS)</measure>
    <time_frame>14 weeks</time_frame>
    <description>Self-report questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Behaviours Questionnaire (SBQ)</measure>
    <time_frame>14 weeks</time_frame>
    <description>Self-report questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate variability (HRV)</measure>
    <time_frame>14 weeks</time_frame>
    <description>Heart rate monitoring with chest strap and Polar watch</description>
  </other_outcome>
  <other_outcome>
    <measure>Acceptance and Action Questionnaire-2 (AAQ-2)</measure>
    <time_frame>14 weeks</time_frame>
    <description>Self-report questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Pain Catastrophizing Scale (PCS)</measure>
    <time_frame>14 weeks</time_frame>
    <description>Self-report questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>14 weeks</time_frame>
    <description>Self-report questionnaire</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Behavioural experiments (CBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Behavioural experiments involve selecting a specific thought to be tested (e.g., &quot;uncertainty makes me unable to act&quot;) and designing a detailed experiment to test out the thought.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Waiting list</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>12 week wait (with assessments) before being transferred to the experimental condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioural experiments for intolerance of uncertainty (BE-IU)</intervention_name>
    <arm_group_label>Behavioural experiments (CBT)</arm_group_label>
    <other_name>CBT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1) at least 18 years of age; 2) principal diagnosis of GAD; 3) no change in medication type&#xD;
        or dose in 4 to 12 weeks before study entry (4 weeks for benzodiazepines, 12 weeks for&#xD;
        antidepressants and hypnotics); 4) willingness to keep medication status stable while&#xD;
        participating in the study; 5) no use of herbal products known to have CNS effects in the 2&#xD;
        weeks before study entry; 6) no evidence of suicidal intent (based on clinical judgement);&#xD;
        7) no evidence of current substance abuse, current or past schizophrenia, bipolar disorder&#xD;
        or organic mental disorder; 8) no current participation in other trials; 9) no concurrent&#xD;
        psychotherapy during treatment phase of trial; 10) no evidence of anxiety symptoms due to a&#xD;
        general medical condition based on clinical judgement (e.g., clinical hyperthyroidism,&#xD;
        hypoglycaemia, anaemia).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel J Dugas, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université du Québec en Outaouais</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Université du Québec en Outaouais</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8X 3X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 15, 2015</study_first_submitted>
  <study_first_submitted_qc>September 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universite du Quebec en Outaouais</investigator_affiliation>
    <investigator_full_name>Michel Dugas, Ph.D.</investigator_full_name>
    <investigator_title>Professor of Psychology</investigator_title>
  </responsible_party>
  <keyword>Cognitive-behavioural therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

